Silexion Therapeutics (NASDAQ:SLXN) Posts Earnings Results, Beats Estimates By $16.03 EPS

Silexion Therapeutics (NASDAQ:SLXN) released its quarterly earnings data on Friday. The company reported ($5.17) EPS for the quarter, beating analysts’ consensus estimates of ($21.20) by $16.03, FiscalAI reports.

Silexion Therapeutics Trading Down 8.7%

Shares of SLXN opened at $0.42 on Friday. The firm has a market cap of $176,484.00, a PE ratio of -0.01 and a beta of -0.25. The company’s 50 day simple moving average is $2.42 and its 200-day simple moving average is $8.52. Silexion Therapeutics has a 12-month low of $0.37 and a 12-month high of $80.00.

Analyst Ratings Changes

Several brokerages have commented on SLXN. Maxim Group lowered shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Monday, June 15th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold”.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.